Dynamic Technology Lab Private Ltd Sells 10,659 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Dynamic Technology Lab Private Ltd lessened its position in Inari Medical, Inc. (NASDAQ:NARI) by 31.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,210 shares of the company’s stock after selling 10,659 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Inari Medical were worth $1,185,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Inari Medical by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock worth $287,354,000 after purchasing an additional 30,702 shares during the period. Jennison Associates LLC lifted its position in shares of Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock valued at $90,014,000 after buying an additional 186,617 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Inari Medical by 9.1% during the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock worth $54,546,000 after acquiring an additional 89,108 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Inari Medical by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 465,962 shares of the company’s stock worth $23,787,000 after acquiring an additional 11,990 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Inari Medical by 5.2% in the 4th quarter. Principal Financial Group Inc. now owns 308,903 shares of the company’s stock valued at $15,769,000 after acquiring an additional 15,368 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on NARI. Truist Financial upped their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. Robert W. Baird restated a “neutral” rating and set a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Finally, Oppenheimer initiated coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price target for the company. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $68.00.

Insider Activity

In related news, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $60.47, for a total value of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. This trade represents a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Price Performance

NARI stock opened at $79.97 on Friday. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99. The business has a 50-day simple moving average of $79.91 and a 200 day simple moving average of $62.64. The company has a market cap of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.